Beyond 1 Million Genomes

The Beyond 1 Million Genomes (B1MG) project is helping to create a network of genetic and clinical data across Europe. The project provides coordination and support to the 1+ Million Genomes Initiative (1+MG). This initiative is a commitment of 21 European Member States and Norway to give cross-border access to one million sequenced genomes by 2022. The BM1G project will support the initiative by:

  • Consulting with stakeholders to establish how to access and share the genomic data
  • Developing specifications and guidelines for accessing the data across borders, whilst making sure legal and ethical issues are addressed
  • Driving the adoption and long-term operation of the technical infrastructure established.

But B1MG will go 'beyond' the 1+MG Initiative by creating long-term means of sharing data beyond 2022, and enabling access to beyond 1 million genomes. See the About page for an overview of the project.

Not sure what a 'genome' is? See the Simple guide to the science for an introduction to the biology behind B1MG.

How will the project benefit society?

Better health and treatments for illnesses

Researchers and clinicians will be able to analyse information about our genome together with our clinical and diagnostic information. This will enable them identify patterns that help predict the future development of disease, detect illness earlier, and determine the most effective interventions to improve health.

Economic benefits

Improvements in personalised medicine approaches are predicted to make national health systems more efficient and cost-effective, and the development of new pharmacogenomics (how genes affect a person's response to a drug) will stimulate innovation and new products across the healthcare industry.

Project overview

Goals

  • To work with regional, national and European stakeholders to define the requirements for cross-border access to genomics and personalised medicine data.
  • To translate requirements for data quality, standards, technical infrastructure, and Ethical, Legal, and Social Implications (ELSI) into technical specifications and implementation guidelines that capture European best practice.
  • To drive adoption and support for long-term operations by providing guidance on phased development and a methodology for economic evaluation.

See the About page and Objectives and key results.

Coordinator

Serena Scollen (Head of Human Genomics and Translational Data, ELIXIR)
See How the project is organised.

Participants

28 European partners from 25 countries. Participants are from both academia and industry.
See Participants.

Duration

Three years (June 2020 - May 2023)

Funding

€4M, from the European Union's Horizon 2020 Research and Innovation programme

Contact

b1mg-coordination@elixir-europe.org